Articles are published before they’re reviewed; doubts about a paper are viewed as a positive status; papers only need to contain “science;” review and revision can continue forever; and PubMed Central is their certifying entity. Welcome to the world of F1000 Research. Continue reading
The National Library of Medicine has a couple of powerful brands, but they’ve become conflated and compromised by poor brand management. Ultimately, their brand value is derived from the value of the MEDLINE brand, which may now be spread too thin. Continue reading
F1000 Research has confusing review and publication practices, and doesn’t call itself a journal, yet is now going to be indexed by PubMed — further eroding the PubMed brand. Continue reading
More information emerges about PubMed Central, its processes, its relationship with eLife, and its role as a technology provider. Overall, it looks like certain OA friends get special treatment, and the processes you think occur are often short-circuited and may not even be tracked. Continue reading
Retracted papers continue to persist on public websites, in institutional repositories and personal libraries years after they are formally retracted. What can be done to help correct the scientific record? Continue reading
Should search engines license content for crawling? A potential German law thinks so. Continue reading
What do authors say when they are caught duplicating text and figures from another paper? More than you’d imagine! Continue reading